Julie M. Vose, MD, MBA, FASCO, on the AETHERA trial
2014 ASH Annual MeetingJulie M. Vose, MD, MBA, FASCO, of the University of Nebraska Medical Center, offers her thoughts on abstract 673, “The AETHERA Trial: Results of a Randomized, Double-Blind, Placebo-Controlled Phase III Study of Brentuximab Vedotin in the Treatment of Patients at Risk of Progression Following Autologous Stem Cell Transplant for Hodgkin Lymphoma,” presented by Craig H. Moskowitz, MD.
Related Videos
Hagop Kantarjian, MD, on Inotuzumab Ozogamicin Plus Low-Intensity Chemotherapy in ALL
Hagop Kantarjian, MD, of The University of Texas MD Anderson Cancer Center, offers his thoughts on abstract 794,
Alan F. List, MD, of Moffitt Cancer Center, offers his thoughts on abstract 3251, “An Open-Labe...
Alan F. List, MD, on Sotatercept in Lower-Risk Myelodysplastic Syndromes
Matthew Lunning, DO, on Ublituximab Plus TGR-1202 in Lymphoma
Matthew Lunning, DO, of the University of Nebraska Medical Center, on abstract 801, “Ublituxima...
Richard M. Stone, MD, on the SAL-SORAML Trial
Richard M. Stone, MD, of Dana-Farber Cancer Institute, offers his thoughts on abstract 6,
Sagar Lonial, MD, on Monoclonal Antibodies in Multiple Myeloma
Sagar Lonial, MD, of Winship Cancer Institute, offers his thoughts on abstract 302, “Final Resu...
